These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 11181385)

  • 41. In vitro potency of moxifloxacin, clinafloxacin and sitafloxacin against 248 genetically defined clinical isolates of Staphylococcus aureus.
    Schmitz FJ; Fluit AC; Milatovic D; Verhoef J; Heinz HP; Brisse S
    J Antimicrob Chemother; 2000 Jul; 46(1):109-13. PubMed ID: 10882698
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antibiotic resistance in Staphylococcus aureus and streptococci.
    Lacey RW
    Br Med Bull; 1984 Jan; 40(1):77-83. PubMed ID: 6442875
    [No Abstract]   [Full Text] [Related]  

  • 43. Antibacterial activity of various honey types of Algeria against Staphylococcus aureus and Streptococcus pyogenes.
    Moussa A; Noureddine D; Mohamed HS; Abdelmelek M; Saad A
    Asian Pac J Trop Med; 2012 Oct; 5(10):773-6. PubMed ID: 23043914
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Do bacteria mutate to erythromycin resistance?
    Lacey RW
    Scott Med J; 1977 Dec; 22(5):367-74. PubMed ID: 23582
    [No Abstract]   [Full Text] [Related]  

  • 45. [Annual changes in susceptibility of clinical isolates to midecamycin acetate].
    Deguchi K; Yokota N; Koguchi M; Nakane Y; Fukushima Y; Fukayama S; Ishihara R; Oda S; Tanaka S; Sato K
    Jpn J Antibiot; 1990 Aug; 43(8):1341-52. PubMed ID: 2283704
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Activity of six quinolones against 226 recent clinical isolates of Streptococcus pyogenes with reduced susceptibility to ciprofloxacin.
    Latorre C; García-Rey C; García-Perea A; Perea E; Aguilar L; Cercenado E; García-de-Lomas J;
    J Antimicrob Chemother; 2002 Aug; 50(2):301-3. PubMed ID: 12161418
    [No Abstract]   [Full Text] [Related]  

  • 47. In vitro activity of DX-619, a novel des-fluoro(6) quinolone, against a panel of Streptococcus pneumoniae mutants with characterized resistance mechanisms.
    Wickman PA; Moland ES; Black JA; Thomson KS
    Antimicrob Agents Chemother; 2006 Feb; 50(2):796-8. PubMed ID: 16436749
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Increased in vitro activity of the novel des-fluoro(6) quinolone BMS-284756 against genetically defined clinical isolates of Staphylococcus aureus.
    Schmitz FJ; Boos M; Mayer S; Jagusch H; Fluit AC
    J Antimicrob Chemother; 2002 Feb; 49(2):283-7. PubMed ID: 11815569
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Induction of in vitro resistance to BMS-284756 by Streptococcus pneumoniae.
    Schmitz FJ; Boos M; Jagusch H; Mayer S; Fluit AC; Hafner D
    J Antimicrob Chemother; 2001 Oct; 48(4):588-90. PubMed ID: 11581245
    [No Abstract]   [Full Text] [Related]  

  • 50. In vitro activity of gatifloxacin against Streptococcus pneumoniae isolates in Germany.
    Reinert RR; Al-Lahham A; Lemmen S; Lütticken R
    J Antimicrob Chemother; 2000 Nov; 46(5):854-6. PubMed ID: 11062219
    [No Abstract]   [Full Text] [Related]  

  • 51. Efficacy of quinolones in preventing Staphylococcus aureus-induced abscess in mice.
    Cohen MA; Gage JW; Huband MD; Meservey MA; VanderRoest SR; Yoder SL
    J Antimicrob Chemother; 1995 Sep; 36(3):551-5. PubMed ID: 8830021
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Bacterial resistance and new therapeutic perspectives].
    Muller-Serieys C
    Presse Med; 1998 Dec; 27 Suppl 5():42-6. PubMed ID: 9879336
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Quinolone-resistance mechanisms and in vitro susceptibility patterns among European isolates of Streptococcus mitis, Streptococcus sanguis, and Streptococcus pneumoniae.
    Schmitz FJ; Fisher A; Boos M; Mayer S; Milatovic D; Fluit AC
    Eur J Clin Microbiol Infect Dis; 2001 Mar; 20(3):219-22. PubMed ID: 11347679
    [No Abstract]   [Full Text] [Related]  

  • 54. Quantitative and qualitative determinations of the combined effect of tetracycline and oleandomycin. I. In vitro effect.
    Tone J; Niki K; Maeda H; Ihara I; Kawakami M
    Jpn J Antibiot; 1976 May; 29(5):559-70. PubMed ID: 6805
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Structures of existing and new quinolones and relationship to bactericidal activity against Streptococcus pneumoniae.
    Mitsuyama J
    J Antimicrob Chemother; 1999 Aug; 44(2):201-7. PubMed ID: 10473226
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Single- and multistep resistance selection studies on the activity of retapamulin compared to other agents against Staphylococcus aureus and Streptococcus pyogenes.
    Kosowska-Shick K; Clark C; Credito K; McGhee P; Dewasse B; Bogdanovich T; Appelbaum PC
    Antimicrob Agents Chemother; 2006 Feb; 50(2):765-9. PubMed ID: 16436741
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In vitro activity of gemifloxacin and five other fluoroquinolones against defined isogenic mutants of Escherichia coli, Pseudomonas aeruginosa and Staphylococcus aureus.
    Schulte A; Heisig P
    J Antimicrob Chemother; 2000 Dec; 46(6):1037-8. PubMed ID: 11102429
    [No Abstract]   [Full Text] [Related]  

  • 58. Fluoroquinolone resistance among recent clinical isolates of Streptococcus pneumoniae.
    Barry AL; Brown SD; Fuchs PC
    J Antimicrob Chemother; 1999 Mar; 43(3):428-9. PubMed ID: 10223606
    [No Abstract]   [Full Text] [Related]  

  • 59. Will pneumococci put quinolones in their place?
    Legg JM; Bint AJ
    J Antimicrob Chemother; 1999 Oct; 44(4):425-7. PubMed ID: 10588301
    [No Abstract]   [Full Text] [Related]  

  • 60. [Penetration into bone and joint tissues of rabbits and in vitro antibacterial activity of tosufloxacin].
    Yamashiro Y; Nunome M; Takahata M; Yasuda T
    Jpn J Antibiot; 1993 Jan; 46(1):31-5. PubMed ID: 8384277
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.